An Indiana University affiliated startup, Allinaire Therapeutics LLC (Allinaire), is ready to enter its next phase of growth through a new partnership with the global pharmaceutical and healthcare company Chiesi Farmaceutici S.p.A. (Chiesi Group).
Chiesi’s new investment in Allinaire will advance research into the treatment of pulmonary arterial hypertension (PAH), a rare pulmonary condition causing high blood pressure in the blood vessels of the lungs, leading to heart failure.
Chiesi’s announcement marks its acquisition of global rights to Allinaire’s portfolio of therapeutic monoclonal antibodies (mAbs) against endothelial monocyte-activating polypeptide II (EMAP II), also known as anti-EMAP II mAbs.
The anti-EMAP II treatment uses lab-created monoclonal antibodies (mAbs) that can specifically bind and neutralize a toxic protein that leads to pulmonary hypertension development. The global therapeutic monoclonal antibodies market is growing rapidly, drawing attention to its potential as a treatment option.
Allinaire’s anti-EMAP II antibody technology is licensed from Indiana University.
“This agreement strengthens Chiesi’s commitment to developing novel treatments for conditions with a high unmet medical need, such as pulmonary arterial hypertension,” Thomas Eichholtz, head of global R&D at Chiesi, said in a press release. “We believe that an anti-EMAP II antibody is a promising novel approach for the development of an effective treatment for pulmonary arterial hypertension patients. The partnership with Allinaire is further evidence of Chiesi’s focus on innovation and desire to accelerate our entry into biologics and thus diversify our therapeutic platforms.”